Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-04-01 6:21 pm Purchase | 13G | AQUESTIVE THERAPEUTICS INC AQST | Venrock Healthcare Capital Partners III L.P. | 5,555,555 6.5% | 5,555,555 (New Position) | View |
2024-03-04 4:16 pm Purchase | 13G | CENTURY THERAPEUTICS INC IPSC | Venrock Healthcare Capital Partners III L.P. | 3,405,133 5.4% | 3,405,133 (New Position) | View |
2024-02-26 4:15 pm Purchase | 13G | ENGENE HLDGS INC ENGN | Venrock Healthcare Capital Partners III L.P. | 2,565,841 5.9% | 2,565,841 (New Position) | View |
2024-02-14 9:20 pm Purchase | 13G | APPLIED THERAPEUTICS INC APLT | Venrock Healthcare Capital Partners III L.P. | 7,877,817 9.99% | 2,080,232 (+35.88%) | View |
2024-02-14 9:13 pm Unchanged | 13G | AVALO THERAPEUTICS INC PAR AVTX | Venrock Healthcare Capital Partners III L.P. | 0 0% | 0 (Unchanged) | View |
2024-02-14 8:56 pm Purchase | 13G | MERSANA THERAPEUTICS INC MRSN | Venrock Healthcare Capital Partners III L.P. | 11,328,000 9.4% | 1,650,000 (+17.05%) | View |
2024-02-14 8:56 pm Sale | 13G | MILESTONE PHARMACEUTICALS INC MIST | Venrock Healthcare Capital Partners III L.P. | 925,048 2.8% | -1,283,764 (-58.12%) | View |
2024-02-14 8:53 pm Purchase | 13G | CABALETTA BIO INC CABA | Venrock Healthcare Capital Partners III L.P. | 2,563,952 6.4% | 668,667 (+35.28%) | View |
2024-02-14 8:53 pm Purchase | 13G | ENLIVEN THERAPEUTICS INC ELVN | Venrock Healthcare Capital Partners III L.P. | 2,954,902 7.2% | 740,760 (+33.46%) | View |
2024-02-14 8:52 pm Purchase | 13G | KALVISTA PHARMACEUTICALS INC C KALV | Venrock Healthcare Capital Partners III L.P. | 4,824,731 14% | 1,251,017 (+35.01%) | View |
2024-02-14 8:51 pm Purchase | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | Venrock Healthcare Capital Partners III L.P. | 4,400,000 8.9% | 1,512,483 (+52.38%) | View |
2024-02-14 8:47 pm Purchase | 13G | SPYRE THERAPEUTICS, INC SYRE | Venrock Healthcare Capital Partners III L.P. | 3,734,514 9.99% | 3,734,514 (New Position) | View |
2024-02-14 8:45 pm Purchase | 13G | PRAXIS PRECISION MEDICINES INC PRAX | Venrock Healthcare Capital Partners III L.P. | 823,626 8.9% | 823,626 (New Position) | View |
2024-02-14 8:44 pm Purchase | 13G | RAYZEBIO INC RYZB | Venrock Healthcare Capital Partners III L.P. | 4,030,471 6.7% | 13,624 (+0.34%) | View |
2024-02-14 8:44 pm Sale | 13G | TAYSHA GENE THERAPIES INC TSHA | Venrock Healthcare Capital Partners III L.P. | 10,412,872 5.6% | -4,031,572 (-27.91%) | View |
2024-02-14 8:42 pm Purchase | 13G | PHARVARIS N V REGISTERED PHVS | Venrock Healthcare Capital Partners III L.P. | 3,395,606 6.5% | 912,000 (+36.72%) | View |
2024-02-14 8:38 pm Purchase | 13G | TERNS PHARMACEUTICALS INC TERN | Venrock Healthcare Capital Partners III L.P. | 4,497,117 7.3% | 789,226 (+21.29%) | View |
2024-02-14 8:28 pm Purchase | 13G | VIRIDIAN THERAPEUTICS INC VRDN | Venrock Healthcare Capital Partners III L.P. | 5,555,568 9.99% | 1,324,947 (+31.32%) | View |
2024-02-14 8:28 pm Purchase | 13G | CELCUITY INC CELC | Venrock Healthcare Capital Partners III L.P. | 2,476,980 9.99% | 2,476,980 (New Position) | View |
2024-02-14 8:26 pm Purchase | 13G | ADVERUM BIOTECHNOLOGIES INC CO ADVM | Venrock Healthcare Capital Partners III L.P. | 15,564,213 7.5% | 9,664,724 (+163.82%) | View |